Tempest Therapeutics (TPST)’ PPARalpha inhibitor, a treatment of hepatocellular carcinoma, received FDA orphan designation, according to a post on the agency’s site.
Pick the best stocks and maximize your portfolio:
- Discover top-rated stocks from highly ranked analysts with Analyst Top Stocks!
- Easily identify outperforming stocks and invest smarter with Top Smart Score Stocks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on TPST:
- Tempest Therapeutics Reports Q3 2024 Financial Results
- Tempest Therapeutics price target lowered to $5 from $8 at Piper Sandler
- Tempest Therapeutics reports Q3 EPS (41c), consensus (36c)
- Tempest receives FDA study may proceed for Phase 3 trial of amezalpat
- Tempest Therpeutics options imply 22.5% move in share price post-earnings